Alto Neuroscience (ANRO)
Develops neuropsychiatric drug candidates for biomarker-defined patient populations.
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $37.25 Average PT from Analysts
Shares of Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have issued a buy recommendation on
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026. Mr. Smith will continue to lead Alto's finance function and oversee corporate strategy and business development, reporting to Amit Etkin, M.D., Ph.D., Alto's founder, chief executive officer and c.
AWM Investment Company Inc. Purchases New Holdings in Alto Neuroscience, Inc. $ANRO
AWM Investment Company Inc. bought a new position in shares of Alto Neuroscience, Inc. (NYSE: ANRO) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 80,000 shares of the company's stock, valued at approximately $2,111,000. AWM Investment Company Inc. owned approximately 0.23% of
Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High – Still a Buy?
Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $36.99 and last traded at $36.4220, with a volume of 867909 shares traded. The stock had previously closed at $34.28. Analyst Upgrades and Downgrades Several research firms recently
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of “Moderate Buy” by Analysts
Shares of Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven analysts that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have issued a buy
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected.
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today highlighted the publication in Nature Medicine of PRIME-PRAXOL, an independent, randomized, double-blind, placebo-controlled trial of the dopamine agonist pramipexole in patients with mood disorders and clinically significant anhedonia. The study was conducted and independently funded by investigators at Lund University, Sweden. Adults with elevated baseline anhedonia symptoms with a diagnosis of major d.
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
Alto Neuroscience, Inc. (âAltoâ) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuro
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. “We are thrilled to welcome Andrew to Alto's Board at a transformative time for the Company,” said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuros.
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin, M.D., Ph.D. on receiving the Transformational Research Award from the VP&S Alumni Association at Columbia University Vagelos College of Physicians and Surgeons. This award honors VP&S alumni who are making transformational contributio.
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended March 31, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. “2026 is off to a strong start across our pipeline, highlighted by the initiation of the Phase 2b trial of ALTO-207 in T.
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in the following upcoming investor conferences: Bank of America Securities Healthcare Conference, May 12-14, 2026 Format: Company presentation and one-on-one meetings Presentation Date & Time: May 1.
Alto Neuroscience (NYSE:ANRO) Shares Gap Down Following Analyst Downgrade
Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report)'s share price gapped down before the market opened on Thursday after Robert W. Baird lowered their price target on the stock from $41.00 to $38.00. The stock had previously closed at $23.41, but opened at $20.00. Robert W. Baird currently has an outperform rating on the stock.
Alto Neuroscience Announces $120 Million Private Placement Financing
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting offering expenses. The financing.
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full year ended December 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. “Alto enters 2026 with a very strong clinical and financial foundation,” said Amit Etkin, M.D., Ph.D., founder and.
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference, March 2-5, 2026 Format: Fireside chat and one-on-one meetings Presentation Date & Time: March 3, 2026, 1:50.
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #Neuroplasticity--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, "Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments," in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience's leadership team, Patricio O'Donn.
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #ACNP--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations highlighting new data and analyses supporting the Company's development programs at the 64th annual meeting of the American College of Neuropsychopharmacology (ACNP) held January 12-15, 2026. “We are pleased to have the opportunity to showcas.
Alto Neuroscience (NYSE:ANRO) Trading Down 6% – Here’s Why
Shares of Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report) were down 6% during mid-day trading on Friday. The company traded as low as $16.90 and last traded at $16.74. Approximately 59,931 shares changed hands during trading, a decline of 86% from the average daily volume of 425,848 shares. The stock had previously closed
Alto Neuroscience, Inc. $ANRO Shares Sold by AWM Investment Company Inc.
AWM Investment Company Inc. trimmed its stake in shares of Alto Neuroscience, Inc. (NYSE: ANRO) by 68.9% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 280,483 shares of the company's stock after selling 621,501 shares during the